Diabelup, a fast-growing company specializing in diabetes, discontinued its Series C fundraiser – led by LBO France, joined by Terumo Corporation, Innovacum and backed by its historic partners – to continue developing its business activity and establish itself internationally.
Diabeloop receives 70 million euros to continue developing its powerful and sustainable strategy
Diabelup, a pioneer of automated insulin administration, develops self-learning software for the treatment of diabetes. Its highly sophisticated algorithms have been integrated into easy-to-use solutions that facilitate the management of chronic diseases, have a strong impact on clinical outcomes and the quality of life of people with diabetes.
Diabelup has seen strong growth in recent years, especially with two solutions available in the European market, reaching nearly 10,000 people a year after its commercial launch. This period was marked by major developments in projects with various medical device partners.
The first semi-closed loop solutions marketed by Diabelup enable automatic and personalized management of type 1 diabetes and highly unstable type 1 diabetes. Combining an uninterrupted glucose sensor (CGM) and an insulin pump, advanced algorithms developed by Diabelup analyze data in real time and deliver insulin automatically. It transforms the lives of patients who have to make many therapeutic decisions and significantly reduces the emotional load associated with therapeutic rhythms.
Eric HuneckerThe founder and CEO of Diabelup has announced that ” Since 2021 we have been able to bring our solutions to thousands of patients and see their enthusiasm, which is why we are all working hard at Diabelope. The success of the teams during this fundraising but great opportunity to come to the fore was recognized today.. A
Private equity is a key player in raising funds, French LBO. The venture capital division of private equity is a European leader in e-health and supports young companies with ambitious projects that are internationally oriented.
Diabelup teams have created a unique data-driven solution that could revolutionize the daily lives of millions of diabetics by relieving them of their mental burdens and significantly improving their disease control. We are happy to be here. ” Says Valerie HutPartner, LBO France Venture Head.
Terumo Corporation, World leader in medical technology, also participated in this funding round. Following an initial partnership in 2020, Terumo Corporation has extended its contract for a global strategic partnership with Diabelup in 2021.
” We are delighted that Diabloop has crossed this important milestone with flying colors and continues to develop international opportunities. We are committed to Diabeloop helping to provide personalized and patient-centered solutions for all stakeholders. “Commented Hikaru SamejimaPresident of Terumore Medical Care Solutions Business.
InnovacumA key player in the ecosystem of French and European startups, specializing in industrial and deep-technology projects, LBO joins France and Terumo Corporation as a new investor.
Encouraged by the commercial development of Diabelup’s first solutions and its groundbreaking innovation to address the 10 million patient market in the medium term, previous investors CERITD, CEMAG Investments, Kreaxi, Supernova Invest, AGIR A DOM., Credit Agricole, Odyssee Venture, UI Investissement (Sofimac) and Promontoires Everyone has decided to reinvest. Also, Bpifrance and the historic banking pool support Diabeloop through loan financing.
“We are grateful for the confidence shown to us by our historic investors and proud of the new industry and financial shareholders who have joined us. I have full confidence in the commitment and talent of the Diabloop team to follow and expand our innovation approach and add value for patients and thus become a leader and trusted partner in this much-needed diabetes market. A Conclusion Catherine DunandPresident of the Board of Directors of Diabelup.
In 2019, Diabelup Therapeutic raised the largest European fund in artificial intelligence to support the commercial launch of two solutions, equipping thousands of patients today. Their CE-marked data visualization platform supports healthcare professionals and patients as telemedicine and remote monitoring solutions. Influential projects – such as the adaptation of early algorithms to the integrated pen market, which have millions of users, and the development of integrated clocks – have also contributed to the great speed of Diabloop.